Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID … – Virology Journal

Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 202021. Lancet. 2022;399(10334):151336.

Article CAS Google Scholar

Mostafa-Hedeab G. ACE2 as drug target of COVID-19 virus treatment, simplified updated review. Rep Biochem Mol Biology. 2020;9(1):97.

Article CAS Google Scholar

Yu W-L, Toh HS, Liao C-T, Chang W-T. Cardiovascular complications of COVID-19 and associated concerns: a review. Acta Cardiol Sinica. 2021;37(1):9.

Google Scholar

Page EM, Arins RA. Mechanisms of thrombosis and cardiovascular complications in COVID-19. Thromb Res. 2021;200:18.

Article CAS PubMed PubMed Central Google Scholar

Liu L, Jing H, Wu X, Xiang M, Novakovic VA, Wang S et al. The cross-talk of lung and heart complications in COVID-19: endothelial cells dysfunction, thrombosis, and treatment. Front Cardiovasc Med. 2022;9.

Shehata GA, Lord KC, Grudzinski MC, Elsayed M, Abdelnaby R, Elshabrawy HA. Neurological complications of COVID-19: underlying mechanisms and management. Int J Mol Sci. 2021;22(8):4081.

Article CAS PubMed PubMed Central Google Scholar

Al-Karmalawy AA, Soltane R, Abo Elmaaty A, Tantawy MA, Antar SA, Yahya G, et al. Coronavirus disease (COVID-19) control between drug repurposing and vaccination: a comprehensive overview. Vaccines. 2021;9(11):1317.

Article CAS PubMed PubMed Central Google Scholar

Ashour NA, Abo Elmaaty A, Sarhan AA, Elkaeed EB, Moussa AM, Erfan IA et al. A systematic review of the global intervention for SARS-CoV-2 combating: from drugs repurposing to molnupiravir approval. Drug design, development and therapy. 2022:685715.

Ritonavir-Boosted Nirmatrelvir. (Paxlovid) [ https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/.

Ghasemiyeh P, Mohammadi-Samani S. COVID-19 outbreak: challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. Heart Lung. 2020;49(6):76373.

Article PubMed PubMed Central Google Scholar

Ghasemiyeh P, Borhani-Haghighi A, Karimzadeh I, Mohammadi-Samani S, Vazin A, Safari A, et al. Major neurologic adverse drug reactions, potential drugdrug interactions and pharmacokinetic aspects of drugs used in covid-19 patients with stroke: a narrative review. Ther Clin Risk Manag. 2020;16:595.

Article CAS PubMed PubMed Central Google Scholar

Ghasemiyeh P, Mortazavi N, Karimzadeh I, Vazin A, Mahmoudi L, Moghimi-Sarani E, et al. Psychiatric adverse drug reactions and potential Anti-COVID-19 drug interactions with psychotropic medications. Iran J Pharm Research: IJPR. 2021;20(3):66.

CAS PubMed PubMed Central Google Scholar

Ghasemiyeh P, Mohammadi-Samani S. Iron chelating agents: promising supportive therapies in severe cases of COVID-19? Trends Pharm Sci. 2020;6(2):656.

CAS Google Scholar

Ghasemiyeh P, Mohammadi-Samani S, Vazin A. Micronutrients supplementation in pregnant women during COVID-19 pandemy: pros and cons. Trends Pharm Sci. 2021;7(3):15360.

CAS Google Scholar

Zarkesh K, Entezar-Almahdi E, Ghasemiyeh P, Akbarian M, Bahmani M, Roudaki S, et al. Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. Future Microbiol. 2021;16(18):141551.

Article CAS PubMed Google Scholar

Ghasemiyeh P, Mohammadi-Samani S. The necessity of early anti-inflammatory therapy initiation in cases with mild-to-moderate COVID-19: a personal experience from an attending pharmacist and his resident. Acta Bio-medica: Atenei Parmensis. 2021;92(3):e2021250e.

PubMed Google Scholar

Vetter P, Vu DL, LHuillier AG, Schibler M, Kaiser L, Jacquerioz F. Clinical features of covid-19. British Medical Journal Publishing Group; 2020.

Pelaia C, Tinello C, Vatrella A, De Sarro G, Pelaia G. Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications. Ther Adv Respir Dis. 2020;14:1753466620933508.

Article CAS PubMed PubMed Central Google Scholar

Bazdyrev E, Rusina P, Panova M, Novikov F, Grishagin I, Nebolsin V. Lung fibrosis after COVID-19: treatment prospects. Pharmaceuticals. 2021;14(8):807.

Article CAS PubMed PubMed Central Google Scholar

Villapol S. Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome. Translational Res. 2020;226:5769.

Article CAS Google Scholar

Shih AR, Misdraji J. COVID-19: gastrointestinal and hepatobiliary manifestations. Hum Pathol. 2023;132:3955.

Article CAS PubMed Google Scholar

Kunutsor SK, Laukkanen JA. Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med. 2020;52(7):34553.

Article CAS PubMed PubMed Central Google Scholar

Gjonbalaj N, Uka S, Olluri E, Sulovari A, Vishaj M, Kamberi L, et al. Renal artery thrombosis as a long-term complication of COVID-19. Radiol Case Rep. 2023;18(1):2605.

Article PubMed Google Scholar

Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, et al. The variety of cardiovascular presentations of COVID-19. Circulation. 2020;141(23):19306.

Article CAS PubMed PubMed Central Google Scholar

Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):15047.

Article PubMed PubMed Central Google Scholar

Sheraton M, Deo N, Kashyap R, Surani S. A review of neurological complications of COVID-19. Cureus. 2020;12(5).

Nagu P, Parashar A, Behl T, Mehta V. CNS implications of COVID-19: a comprehensive review. Rev Neurosci. 2021;32(2):21934.

Article CAS PubMed Google Scholar

Guck AJ, Buck K, Lehockey K. Psychological complications of COVID-19 following hospitalization and ICU discharge: recommendations for treatment. Professional Psychology: Research and Practice; 2021.

Google Scholar

Alahyari S, Moradi M, Rajaeinejad M, Jalaeikhoo H. Post-COVID-19 hematologic complications: a systematic review. Expert Rev Hematol. 2022(just-accepted).

Fanaroff AC, Lopes RD. COVID-19 thrombotic complications and therapeutic strategies. Annu Rev Med. 2023;74:1530.

Article CAS PubMed Google Scholar

Bouzid D, Visseaux B, Kassasseya C, Daoud A, Fmy F, Hermand C, et al. Comparison of patients infected with Delta versus Omicron COVID-19 variants presenting to Paris emergency departments: a retrospective cohort study. Ann Intern Med. 2022;175(6):8317.

Article PubMed Google Scholar

Therapeutic Management of Nonhospitalized Adults With COVID. -19 [ https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/#:~:text=The%20Panel%20recommends%20using%20nirmatrelvir,of%20symptom%20onset%20(%20AIIa%20).

Therapeutic Management of Hospitalized Adults With COVID. -19 [ https://www.covid19treatmentguidelines.nih.gov/tables/therapeutic-management-of-hospitalized-adults/.

Coronavirus Disease. 2019 (COVID-19) Treatment Guidelines [ https://www.covid19treatmentguidelines.nih.gov/.

Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):161220.

Article CAS PubMed PubMed Central Google Scholar

Thiruchelvam K, Kow CS, Hadi MA, Hasan SS. The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. Expert Rev anti-infective Therapy. 2022;20(2):21129.

Article CAS PubMed Google Scholar

Gupte V, Hegde R, Sawant S, Kalathingal K, Jadhav S, Malabade R, et al. Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database. BMC Infect Dis. 2022;22(1):18.

Article CAS PubMed PubMed Central Google Scholar

Remdesivir [Available from. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/remdesivir/.

Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and paxlovid) for COVID-19: a meta-analysis. Ann Med. 2022;54(1):51623.

Article CAS PubMed PubMed Central Google Scholar

Tanne JH. Covid-19: FDA authorises pharmacists to prescribe Paxlovid. British Medical Journal Publishing Group; 2022.

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):50920.

Article PubMed Google Scholar

McCreary EK, Kip KE, Collins K, Minnier TE, Snyder GM, Steiner A, et al. editors. Evaluation of Bebtelovimab for treatment of COVID-19 during the SARS-CoV-2 Omicron variant era. Open Forum Infectious Diseases; 2022.

Kozani PS, Sheikhi M, Baharifar N, Shokoohi SD, Sheikhi S, Mirarefin SMJ et al. Bebtelovimab: the FDA-approved monoclonal antibody for treating patients with mild-to-moderate COVID-19. Trends Med Sci. 2022;2(3).

Vilobelimab [Available from. https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new/.

Kuritzkes DR. Bamlanivimab for Prevention of COVID-19. JAMA. 2021;326(1):312.

Article CAS PubMed Google Scholar

Herman GA, OBrien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, et al. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2022;22(10):144454.

Article CAS PubMed PubMed Central Google Scholar

Ao G, Li A, Wang Y, Tran C, Qi X. Lack of efficacy for sotrovimab use in patients with COVID-19: a meta-analysis. J Infect. 2022.

Jorda A, Kussmann M, Kolenchery N, Siller-Matula JM, Zeitlinger M, Jilma B, et al. Convalescent plasma treatment in patients with Covid-19: a systematic review and Meta-analysis. Front Immunol. 2022;13:817829.

Article CAS PubMed PubMed Central Google Scholar

Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, et al. Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a meta-analysis. JAMA Netw open. 2022;5(1):e2147331e.

Article PubMed PubMed Central Google Scholar

Kirkham AM, Bailey AJ, Monaghan M, Shorr R, Lalu MM, Fergusson DA, et al. Updated Living Systematic Review and Meta-analysis of controlled trials of mesenchymal stromal cells to treat COVID-19: a Framework for Accelerated Synthesis of Trial evidence for Rapid ApprovalFASTER approval. Stem Cells Translational Med. 2022;11(7):67587.

Article Google Scholar

Dorward J, Yu L-M, Hayward G, Saville BR, Gbinigie O, Van Hecke O, et al. Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial. Br J Gen Pract. 2022;72(720):e44655.

Article PubMed PubMed Central Google Scholar

Ghaith HS, Gabra MD, Nafady MH, Elshawah HE, Negida A, Mushtaq G et al. A review of the rational and current evidence on colchicine for COVID-19. Curr Pharm Design. 2022.

Griesel M, Wagner C, Mikolajewska A, Stegemann M, Fichtner F, Metzendorf M-I et al. Inhaled corticosteroids for the treatment of COVID-19. Cochrane Database Syst Reviews. 2022(3).

Clemency BM, Varughese R, Gonzalez-Rojas Y, Morse CG, Phipatanakul W, Koster DJ, et al. Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial. JAMA Intern Med. 2022;182(1):429.

Article CAS PubMed Google Scholar

Nyirenda JL, Sofroniou M, Toews I, Mikolajewska A, Lehane C, Monsef I et al. Fluvoxamine for the treatment of COVID-19. Cochrane Database Syst Reviews. 2022(9).

Mehta P, Chambers RC, Dagna L. Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe? Lancet Rheumatol. 2021;3(6):e3945.

Article CAS PubMed PubMed Central Google Scholar

Lee TC, McDonald EG, Butler-Laporte G, Harrison LB, Cheng MP, Brophy JM. Remdesivir and systemic corticosteroids for the treatment of COVID-19: a bayesian re-analysis. Int J Infect Dis. 2021;104:6716.

Article CAS PubMed PubMed Central Google Scholar

Noreen S, Maqbool I, Madni A, Dexamethasone. Therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol. 2021;894:173854.

Article CAS PubMed PubMed Central Google Scholar

Martinez-Guerra BA, Gonzalez-Lara MF, Roman-Montes CM, Tamez-Torres KM, Dardn-Fierro FE, Rajme-Lopez S, et al. Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study. Emerg Microbes Infections. 2022;11(1):509.

Article CAS Google Scholar

View original post here:

Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID ... - Virology Journal